Recent Analysts’ Ratings Updates for Keros Therapeutics (KROS)
by Scott Moore · The Cerbat GemSeveral brokerages have updated their recommendations and price targets on shares of Keros Therapeutics (NASDAQ: KROS) in the last few weeks:
- 12/19/2025 – Keros Therapeutics was upgraded by analysts at TD Cowen to a “hold” rating.
- 12/15/2025 – Keros Therapeutics had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 12/8/2025 – Keros Therapeutics had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 12/1/2025 – Keros Therapeutics had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 11/28/2025 – Keros Therapeutics had its price target raised by analysts at Bank of America Corporation from $18.00 to $19.00. They now have a “neutral” rating on the stock.
- 11/24/2025 – Keros Therapeutics had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 11/17/2025 – Keros Therapeutics had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
- 11/12/2025 – Keros Therapeutics had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $27.00 price target on the stock, up previously from $23.00.
- 11/11/2025 – Keros Therapeutics had its price target lowered by analysts at Wells Fargo & Company from $26.00 to $23.00. They now have an “overweight” rating on the stock.
- 11/7/2025 – Keros Therapeutics was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
- 11/6/2025 – Keros Therapeutics had its price target raised by analysts at Wedbush from $15.00 to $16.00. They now have a “neutral” rating on the stock.
Insider Activity at Keros Therapeutics
In other news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the company’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The SEC filing for this sale provides additional information. Corporate insiders own 20.60% of the company’s stock.
Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.
The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.